Cullinan Therapeutics, Inc. CGEM 深 沪
已收盘 07-02 16:00:00 美东时间
17.63
+0.350
+2.03%
华盛通- 最 高18.10
- 今 开17.43
- 成交量 107.48万股
- 最 低 17.19
- 昨 收 17.28
- 总市值 10.84亿
- 52周最高 19.4299
- 市盈率 静 --
- 换手率 1.75%
- 52周最低 5.68
- 委 比 78.21%
- 总股本 6145.80万
- 历史最高 59.85
- 量 比 0.84
- 振 幅 5.27%
- 历史最低 5.68
- 每 手 1
- 风险率 3.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
Cullinan Management ( ($CGEM) ) has shared an announcement. On June 10, 2026, C...
06-10 20:00
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion
06-08 15:42
Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studiesInitial data from the first multi-dose cohort of RA study to be
05-26 19:03
Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that
05-19 05:04
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.87) by 13.79 percent. This is a 1.35 percent decrease over losses of $(0.74) per share
05-07 20:35
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
